drugset / Trial / NCT00828997

Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar®

NCT00828997

Phase 4 Completed 505 enrolled Region Skane Lund University · collab
NaSingle-groupOpen-labelPrevention

Summary

Previous studies have analyzed serological responses following pneumococcal vaccination using 23-valent vaccination (Pneumovax) in Rheumatoid Arthritis (RA) patients that were on different therapeutic modalities including TNF-blockers and methotrexate. The results have shown that serological response was significantly reduced in RA patients receiving methotrexate compared to those receiving TNF-blockers. In contrast when using polypeptide immunisation (influenza vaccine) we found that anti-TNF significantly impaired the serological response compared to the methotrexate treated RA patients. The aim of this study is to analyze serological responses after Prevenar vaccination in patients with chronic arthritis and to study the impact of different treatment modalities on serological responses. It will be of interest to see if the result is different compared to the one seen after immunizing with 23-valent nonconjugated pneumococcal polysaccharide vaccine.

Timeline

Start
2008-08
Primary completion
2018-01
Completion
2018-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Prevnar 13 Vaccine 0.5 ml Intramuscular